The document describes a biotechnology company that focuses on regenerative medicine for wound care, angiogenesis, and inflammation. It discusses the AutoloGel System, which uses a patient's own blood-derived growth factors, cytokines, and chemokines to re-establish the natural, balanced environment needed for wound healing. Clinical studies show AutoloGel is effective at healing chronic wounds and costs less than alternative therapies like negative pressure wound therapy. The AutoloGel System provides the necessary proteins for wound repair and creates an optimal environment for healing.

1. A biotechnology company focused on regenerative medicine in the areas of wound care, angiogenesis, and inflammation. Advanced Tissue Regeneration Technologies

2. A biotechnology company focused on regenerative medicine in the areas of wound care, angiogenesis, and inflammation. Advanced Tissue Regeneration Technologies

3. RESTORE THE BALANCE

4. The AutoloGel System™

5. The Science

7. Normal “Complex” Wound Repair Reprinted by permission from Macmillan Publishers Ltd.©2007

8. Wound Repair Proteins Role in Healing

10. Chronic Wound – Stuck in Inflammatory Singer AJ, Clarke RA, (1999) Cutaneous wound healing NEJM ©1999 Massachussetts Medical Society, All Rights Reserved

12. Restore The Balance

13. The AutoloGel ™ System

16. Re established balance to Wound Bed Reprinted by permission from Macmillan Publishers Ltd.©2007

18. The Evidence

20. AutoloGel System™ Randomized Controlled Trial in Diabetic Foot Ulcer Source: Driver VR, Hanft J, Fylling C, Beriou JM. A Prospective Randomized Controlled Trial of Autologous PRP Gel for the Treatment of Diabetic Ulcers. Ostomy & Wound Management . Jun 2006; 52(6):68-87. Majority Wounds n= 35 ≤ 7 cm 2 in Area and ≤ 2 cm 3 in Volume 81.3% Healed 42.1% Healed p = 0.0364 Number Wounds Significantly more healing (81.3%) with AutoloGel™ Mean time to healing was 6 weeks with AutoloGel™

22. Sensitivity Analysis: AutoloGel vs Alternative Therapies Costs over 5 Years (2006 USD) Fylling C, Dougherty E. Evidence Based Cost Effectiveness of Platelet Rich Plasma (PRP) Gel versus Alternative Therapies for the Treatment of Diabetic Foot Ulcers. Poster and Oral Presentations. Clinical Symposium on Advances in Skin & Wound Care October 26-30, 2008

23. Sensitivity Analysis: AutoloGel vs Alternative Therapies QALY over 5 Years (Quality – Adjusted Life Years) Fylling C, Dougherty E. Evidence Based Cost Effectiveness of Platelet Rich Plasma (PRP) Gel versus Alternative Therapies for the Treatment of Diabetic Foot Ulcers. Poster and Oral Presentations. Clinical Symposium on Advances in Skin & Wound Care October 26-30, 2008

24. The AutoloGel System

29. The Experience

31. AutoloGel Case Study Series Right Ischial Pressure Ulcer Arrows Indicate Extent of Undermining Wound Duration: 2 yrs Healed: 1 Month L = 4.7 cm W = 4.2 cm D = 2.3 cm Source: Data on File, Cytomedix, Inc.

32. AutoloGel Case Study Series: Abdominal Dehiscence with Undermining Source: Data on File, Cytomedix, Inc. Patient 64 year old male Initial wound volume (cm 3 ) 212.6 Provider Ambulatory clinic Change in Volume Full closure Previous wound duration 5+ years Weeks to this volume reduction: 5 ½ Wound severity Full thickness No. of AutoloGel Treatments 6

33. AutoloGel Case Study Series: Ischial Pressure Ulcer following NPWT 3 weeks of NPWT 5 weeks of AutoloGel NPWT AutoloGel Source: Data on File, Cytomedix, Inc. Patient 49 yr old paraplegic female Initial wound volume (cm 3 ) 1.75 cm 3 4.87 cm 3 Provider Home Care Change in Volume +178% Full closure Previous wound duration Weeks to this volume change 3 5 Wound severity Stage IV No. of AutoloGel Treatments 6

34. AutoloGel Case Study Series: Heel Pressure Ulcer; Paraplegic w/Spina Bifda Source: Data on File, Cytomedix, Inc. Patient 27 year old male Initial wound Area/Volume Area – 6.09 cm 2 Volume – 3.04 cm 3 Provider Home care Change in Area/Volume Full closure Previous wound duration 156 weeks (3 years) Weeks to this endpoint 7.3 weeks Wound severity Stage III No. of AutoloGel™ Treatments 7

35. AutoloGel Case Study Series: Stage IV Coccygeal Source: Data on File, Cytomedix, Inc. Patient 64 year old male Initial wound Area/Volume Area – 88.0 cm 2 Volume – 219 cm 3 Provider Long term care Change in Volume 99% Volume Reduction Previous wound duration > 1 year Weeks to this endpoint 10 weeks Wound severity Stage IV No. of AutoloGel™ Treatments 12

36. AutoloGel Case Study Series: Bilateral Trochantric Ulcer following NPWT NPWT AutoloGel L Hip R Hip L Hip R Hip Source: Data on File, Cytomedix, Inc. Patient 76 yr old female Initial wound volume (cm 3 ) 17 cm 3 49 cm 3 3 cm 3 23 cm 3 Provider Long Term Acute Care Change in Volume 84% 54% Full closure Full closure Previous wound duration Weeks to this volume reduction 11.5 11.5 4 4 Wound severity Stage IV No. of AutoloGel Treatments 4 4

39. RESTORE THE BALANCE